Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

Those potential efficacy signals are intriguing, but add up to nothing now. The very little patient information is too little- hard to believe the board would believe otherwise. It is wishful thinking only to pretend it will really benefit patients versus standard comparison agents in a meaningful way- for now.

We all hope that ASCO 2017 or 2018 Shapiro will tell us that the phase 2 ovarian trial is being stopped early due to the benefit seen in the Kevetrin alone or the Kevetrin/ Docetaxel groups.

But potential efficacy? The emphasis is on potential, and there at least we agree.